Search Results

You are looking at 91 - 100 of 145 items for :

  • "genetic counseling" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion

Megan Randall, Kelly Burgess, Lela Buckingham, and Lydia Usha

cancer and germline BRCA mutations are more likely to benefit from platinum-based chemotherapy and PARP inhibitors. 1 , 4 All women diagnosed with OC should be referred for genetic counseling and testing, regardless of family history and age at

Full access

NCCN Policy Summit: Reducing the Cancer Burden Through Prevention and Early Detection

Lindsey Bandini, Alyssa Schatz, Victoria Hood, Nikia Clark, Michael J. Hall, and Robert W. Carlson

screening itself may not be able to be completed via telehealth visits, ancillary services such as genetic counseling, which may lead to referral of patients for risk-appropriate screening, can be. Although many barriers exist, the panelists remained

Full access

EGFR-Mutant Non–Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing

Ammar Sukari, Misako Nagasaka, and Erin Wakeling

genetics clinic for further counseling and testing for hereditary lung cancer syndrome. Her 3 children were also referred for genetic counseling. Discussion Historically, Histology Mattered Lung cancer is the most common cancer worldwide. In

Full access

Advocating for Equity in Cancer Care

James McCanney, Terrell Johnson, Lindsey A.M. Bandini, Shonta Chambers, Lynette Bonar, and Robert W. Carlson

in Oncology (NCCN Guidelines) to create a project plan unique to each patient. For example, the 4R Oncology Program can determine whether a patient has a hereditary risk of breast cancer and needs to be referred to genetic counseling and to

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

a BRCA mutation, all patients should have genetic counseling regarding germline BRCA testing. However, classification of ovarian cancer is evolving beyond BRCA mutations to include molecular data. Ovarian cancer subtypes can now be identified

Full access

Abstracts From the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

guidelines instituted in 2017. We await comparison studies of resectability, survival, and recurrence rates. AB2018-23. Facilitating Obstetrician-Gynecologist Awareness of NCCN Guidelines Through Genetic Counseling Amy Cronister, MS, and Kristi Fissell

Full access

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

family genetic counseling, cancer risk syndromes, and assessment of personal risk for second cancers. Some patients with prostate cancer and their families may be at increased risk for breast and ovarian cancer, melanoma, and pancreatic cancer (HBOC

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

options for maintenance therapy, all patients with histologically confirmed ovarian cancer should undergo genetic risk evaluation and BRCA1 and BRCA2 testing, if not previously performed. However, treatment should not be delayed for genetic counseling

Full access

Molecular Tumor Testing for Lynch Syndrome in Patients With Colorectal Cancer

Jeremy Matloff, Aimee Lucas, Alexandros D. Polydorides, and Steven H. Itzkowitz

-risk individuals. Thus, any formalized process should specifically include the following steps: 1) identifying positive results; 2) contacting the physician who is responsible for the affected individuals; 3) genetic counseling and testing if available and desired

Full access

Mammographic Breast Density: Effect on Imaging and Breast Cancer Risk

Renee W. Pinsky and Mark A. Helvie

as screening MRI and WB-US, and for genetic counseling and risk reduction efforts. EDITOR Kerrin M. Green, MA, Assistant Managing Editor, Journal of the National Comprehensive Cancer Network Disclosure: Kerrin M. Green, MA, has disclosed no relevant